Virologisches Institut, Universitätsklinikum Erlangen, Schlossgarten 4, Erlangen, Germany.
J Virol. 2010 Apr;84(8):4083-8. doi: 10.1128/JVI.02117-09. Epub 2010 Feb 10.
Cytomegalovirus (CMV) infection in patients receiving hematopoietic stem cell transplants (HSCT) is associated with morbidity and mortality. Adoptive T cell immunotherapy has been used to treat viral reactivation but is hardly feasible in high-risk constellations of CMV-positive HSCT patients and CMV-negative stem cell donors. We endowed human effector T cells with a chimeric immunoreceptor (cIR) directed against CMV glycoprotein B. These cIR-engineered primary T cells mediated antiviral effector functions such as cytokine production and cytolysis. This first description of cIR-redirected CMV-specific T cells opens up a new perspective for HLA-independent immunotherapy of CMV infection in high-risk patients.
巨细胞病毒（CMV）感染接受造血干细胞移植（HSCT）的患者与发病率和死亡率相关。过继性 T 细胞免疫疗法已被用于治疗病毒再激活，但在 CMV 阳性 HSCT 患者和 CMV 阴性干细胞供体的高危情况下几乎不可行。我们为人类效应 T 细胞赋予了一种针对 CMV 糖蛋白 B 的嵌合免疫受体（cIR）。这些 cIR 工程化的原代 T 细胞介导了抗病毒效应功能，如细胞因子产生和细胞溶解。对 cIR 重定向的 CMV 特异性 T 细胞的这一首次描述为高危患者 CMV 感染的 HLA 非依赖性免疫治疗开辟了新的视角。
